Appendix A

JurisdictionUnited States
Appendix A Vaccine Injury Compensation Rules, 40 CFR Part 100

Part 100—Vaccine Injury Compensation

Contents

§100.1 Applicability.
§100.2 Average cost of a health insurance policy.
§100.3 Vaccine injury table.

Authority: Secs. 312 and 313 of Public Law 99-660 (42 U.S.C. 300aa-1 note); 42 U.S.C. 300aa-10 to 300aa-34; 26 U.S.C. 4132(a); and sec. 13632(a)(3) of Public Law 103-66.

§100.1 Applicability

This part applies to the National Vaccine Injury Compensation Program (VICP) under subtitle 2 of title XXI of the Public Health Service (PHS) Act.

[60 FR 7693, Feb. 8, 1995]

§100.2 Average Cost of a Health Insurance Policy

For purposes of determining the amount of compensation under the VICP, section 2115(a)(3)(B) of the PHS Act, 42 U.S.C. 300aa-15(a)(3)(B), provides that certain individuals are entitled to receive an amount reflecting lost earnings, less certain deductions. One of the deductions is the average cost of a health insurance policy, as determined by the Secretary. The Secretary has determined that the average cost of a health insurance policy is $363.12 for 2006. This figure is calculated periodically (generally on an annual basis) using the most recent Medical Expenditure Panel Survey-Insurance Component (MEPS-IC) data available as the baseline for the average monthly cost of a health insurance policy. This baseline is adjusted by the annual percentage increase/decrease obtained from the most recent annual Kaiser Family Foundation and Health Research and Educational Trust (KFF/HRET) Employer Health Benefits survey or other authoritative source that may be more accurate or appropriate in the future. The revised amount will be effective upon its delivery by the Secretary to the United States Court of Federal Claims, and the amount will be published as a notice in the Federal Register periodically (generally on an annual basis).

[72 FR 36612, July 5, 2007]

§100.3 Vaccine Injury Table

(a) In accordance with section 312(b) of the National Childhood Vaccine Injury Act of 1986, title III of Public Law 99-660, 100 Stat. 3779 (42 U.S.C. 300aa-1 note) and section 2114(c) of the Public Health Service Act, as amended (PHS Act) (42 U.S.C. 300aa-14(c)), the following is a table of vaccines, the injuries, disabilities, illnesses, conditions, and deaths resulting from the administration of such vaccines, and the time period in which the first symptom or manifestation of onset or of the significant aggravation of such injuries, disabilities, illnesses, conditions, and deaths is to occur after vaccine administration for purposes of receiving compensation under the Program. Paragraph (b) of this section sets forth additional provisions that are not separately listed in this Table but that constitute part of it. Paragraph (c) of this section sets forth the qualifications and aids to interpretation for the terms used in the Table. Conditions and injuries that do not meet the terms of the qualifications and aids to interpretation are not within the Table. Paragraph (d) of this section sets forth a glossary of terms used in paragraph (c).

Vaccine Injury Table


Vaccine

Illness, disability, injury or condition covered

Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration

I. Vaccines containing tetanus toxoid (e.g., DTaP, DTP, DT, Td, or TT)

A. Anaphylaxis

B. Brachial Neuritis

=4 hours.

2-28 days (not less than 2 days and not more than 28 days).

C. Shoulder Injury Related to Vaccine Administration

=48 hours.

D. Vasovagal syncope

=1 hour.

II. Vaccines containing whole cell pertussis bacteria, extracted or partial cell pertussis bacteria, or specific pertussis antigen(s) (e.g., DTP, DTaP, P, DTP-Hib)

A. Anaphylaxis

=4 hours.

B. Encephalopathy or encephalitis

=72 hours.

C. Shoulder Injury Related to Vaccine Administration

=48 hours.

D. Vasovagal syncope

=1 hour.

III. Vaccines containing measles, mumps, and rubella virus or any of its components (e.g., MMR, MM, MMRV)

A. Anaphylaxis

B. Encephalopathy or encephalitis

=4 hours.

5-15 days (not less than 5 days and not more than 15 days).

C. Shoulder Injury Related to Vaccine Administration

=48 hours.

D. Vasovagal syncope

=1 hour.

IV. Vaccines containing rubella virus (e.g., MMR, MMRV)

A. Chronic arthritis

7-42 days (not less than 7 days and not more than 42 days).

V. Vaccines containing measles virus (e.g., MMR, MM, MMRV)

A. Thrombocytopenic purpura

7-30 days (not less than 7 days and not more than 30 days).

B. Vaccine-Strain Measles Viral Disease in an immunodeficient recipient

—Vaccine-strain virus identified

Not applicable.

—If strain determination is not done or if laboratory testing is inconclusive

=12 months.

VI. Vaccines containing polio live virus (OPV)

A. Paralytic Polio

—in a nonimmunodeficient recipient

=30 days.

—in an immunodeficient recipient

=6 months.

—in a vaccine associated community case

Not applicable.

B. Vaccine-Strain Polio Viral Infection

—in a nonimmunodeficient recipient

=30 days.

—in an immunodeficient recipient

=6 months.

—in a vaccine associated community case

Not applicable.

VII. Vaccines containing polio inactivated virus (e.g., IPV)

A. Anaphylaxis

=4 hours.

B. Shoulder Injury Related to Vaccine Administration

=48 hours.

C. Vasovagal syncope

=1 hour.

VIII. Hepatitis B vaccines

A. Anaphylaxis

=4 hours.

B. Shoulder Injury Related to Vaccine Administration

=< 48 hours.

C. Vasovagal syncope

=1 hour.

IX. Haemophilus influenzae type b (Hib) vaccines

A. Shoulder Injury Related to Vaccine Administration

=48 hours.

B. Vasovagal syncope

=1 hour.

X. Varicella vaccines

A. Anaphylaxis

=4 hours.

B. Disseminated varicella vaccine-strain viral disease

—Vaccine-strain virus identified

Not applicable.

—If strain determination is not done or if laboratory testing is inconclusive

7-42 days (not less than 7 days and not more than 42 days).

C. Varicella vaccine-strain viral reactivation

Not applicable.

D. Shoulder Injury Related to Vaccine Administration

=48 hours.

E. Vasovagal syncope

=1 hour.

XI. Rotavirus vaccines

A. Intussusception

1-21 days (not less than 1 day and not more than 21 days).

XII. Pneumococcal conjugate vaccines

A. Shoulder Injury Related to Vaccine Administration

=48 hours.

B. Vasovagal syncope

=1 hour.

XIII. Hepatitis A vaccines

A. Shoulder Injury Related to Vaccine Administration

=48 hours.

B. Vasovagal syncope

=1 hour.

XIV. Seasonal influenza vaccines

A. Anaphylaxis

=4 hours.

B. Shoulder Injury Related to Vaccine Administration

=48 hours.

C. Vasovagal syncope

=1 hour.

D. Guillain-Barré Syndrome

3-42 days (not less than 3 days and not more than 42 days).

XV. Meningococcal vaccines

A. Anaphylaxis

=4 hours.

B. Shoulder Injury Related to Vaccine Administration

=48 hours.

C. Vasovagal syncope

=1 hour.

XVI. Human papillomavirus (HPV) vaccines

A. Anaphylaxis

=4 hours.

B. Shoulder Injury Related to Vaccine Administration

=48 hours.

C. Vasovagal syncope

=1 hour.

XVII. Any new vaccine recommended by the Centers for Disease Control and Prevention for routine administration to children, after publication by the Secretary of a notice of coverage

A. Shoulder Injury Related to Vaccine Administration

=48 hours.

B. Vasovagal syncope

=1hour.

(b) Provisions that apply to all conditions listed. (1) Any acute complication or sequela, including death, of the illness, disability, injury, or condition listed in paragraph (a) of this section (and defined in paragraphs (c) and (d) of this section) qualifies as a Table injury under paragraph (a) except when the definition in paragraph (c) requires exclusion.

(2) In determining whether or not an injury is a condition set forth in paragraph (a) of this section, the Court shall consider the entire medical record.
(3) An idiopathic condition that meets the definition of an illness, disability, injury, or condition set forth in paragraph (c) of this section shall be considered to be a condition set forth in paragraph (a) of this section.

(c) Qualifications and aids to interpretation. The following qualifications and aids to interpretation shall apply to, define and describe the scope of, and be...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT